CompletedPHASE1, PHASE2NCT00061945

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Studying Acute undifferentiated leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Wendy Stock
Cancer and Leukemia Group B
Intervention: allopurinol(drug)
Enrollment: 302 enrolled
Eligibility: 15 years · All sexes
Timeline: 2003 – 2012

Study locations (1)

Cancer and Leukemia Group B, Chicago, Illinois, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00061945 on ClinicalTrials.gov

Other trials for Acute undifferentiated leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06466395
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
M.D. Anderson Cancer Center

See all trials for Acute undifferentiated leukemia →

← Back to all trials